What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to publicly release Amgen's unaudited financial results for the second quarter of 2024, as well as its financial position as of June 30, 2024. It includes a press release that details these results and offers management's perspective using both GAAP and non-GAAP financial measures.

Why does Amgen present non-GAAP financial measures, and what are the main exclusions?

Amgen presents non-GAAP financial measures to provide investors with supplementary information that enhances their understanding of the company's ongoing business performance and facilitates comparisons across periods. Key items excluded from GAAP results to arrive at non-GAAP figures include acquisition-related expenses (like amortization of acquired intangibles), restructuring and cost-saving initiative costs, and certain other unusual or non-recurring items such as gains/losses on equity investments and specific legal settlement-related costs.

What is Free Cash Flow (FCF) and why is it reported?

Free Cash Flow (FCF) is reported as a measure of the company's liquidity. It is calculated by subtracting capital expenditures from operating cash flow, both as determined in accordance with GAAP. Amgen believes FCF provides an additional useful metric for investors to assess the company's ability to generate cash after accounting for investments in its operations.

Where can I find the detailed financial results and the reconciliation of GAAP to non-GAAP measures?

The detailed financial results for the second quarter of 2024, along with the reconciliations of non-GAAP financial measures to their most directly comparable GAAP financial measures, are included in the press release furnished as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on August 6, 2024, furnishing its Second Quarter 2024 earnings press release. The report details the company's financial results for the quarter ended June 30, 2024, and provides an update on its financial condition. A key focus of the filing is the presentation of non-GAAP financial measures, which Amgen uses to offer investors a clearer view of its ongoing business performance by excluding certain items. These excluded items primarily include acquisition-related expenses (such as amortization of acquired intangibles and fair value adjustments to acquired inventory), costs associated with restructuring and cost-saving initiatives, and other non-ordinary course of business items like gains/losses on equity investments and specific legal settlement-related items. The company believes these non-GAAP adjustments, alongside Free Cash Flow (FCF), facilitate better comparisons of performance across periods and enhance understanding of operational profitability and liquidity. Investors should review the press release (Exhibit 99.1) for the specific figures and detailed reconciliations between GAAP and non-GAAP results.

Key Highlights

1Amgen released its Q2 2024 financial results via an 8-K filing on August 6, 2024.
2The filing includes a press release detailing the company's financial performance for the quarter and six months ended June 30, 2024.
3Amgen utilizes and presents non-GAAP financial measures, including non-GAAP EPS, operating income, and net income, to provide supplemental insights.
4Key adjustments to GAAP figures for non-GAAP calculations include acquisition-related expenses, restructuring costs, and certain other income/expense items.
5The company also reports Free Cash Flow (FCF), calculated as cash flow from operations less capital expenditures.
6Management uses these non-GAAP measures internally for budgeting, financial planning, and performance evaluation.
7The provided information is furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless explicitly stated.

AMGEN INC 8-K Report, Financial Results (Aug 6, 2024)

Summary

Key Highlights

Frequently Asked Questions